AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04052412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AraG
Description: All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
Study NCT04871386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT) exercises
Description: The ACT group received 14 (partially succeeding) daily exercises, with each of the following categories being focused twice: Acceptance, contact with the present moment, cognitive defusion, self as context, personal values and committed action. The exercises consisted of metaphors and questions for self-reflection, explanations about emotions and thoughts with techniques to handle them differently, as well as a body scan.
Study NCT04871386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive psychology (PP) exercises
Description: The PP group received 14 daily exercises that were derived from positive psychology interventions that have been proven effective in alleviating clinical symptoms and increasing subjective well-being. In detail, these were: Identifying positive emotions and ways to increase them; Enhancing pleasure from daily activities; Writing a gratitude letter; Identifying and appreciating three personal traits; Receiving a letter of support from one's future self; Taking different perspectives on one's current situation; Envisioning a perfect day; Identifying energy boosters and drainers; Identifying 3 character strengths and using one in a new way; Life review: Writing a legacy; Identifying the positive relationships in one's life; Doing an act of kindness; Three good things; and Coping with failure.
Study NCT00947089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxidized regenerated cellulose (Fibrillar SURGICEL)
Description: one gauze made of ORC
Study NCT00947089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iodoform gauze
Description: one iodoform gauze
Study NCT02143856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg GLPG1205
Description: A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
Study NCT00969605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of two different modes for weaning from mechanical ventilation
Description: Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
Study NCT02514811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Teen Outreach Program
Description: Students received the Teen Outreach Program as described previously.
Study NCT03002324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Survey
Description: The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
Study NCT03002324 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Baseline Survey
Description: The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
Study NCT03002324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Survey
Description: The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
Study NCT03002324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current CDC Message
Description: Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
Study NCT03002324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cervical Cancer Message
Description: Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
Study NCT03002324 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Message
Description: Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
Study NCT03002324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-Intervention Survey
Description: The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
Study NCT03002324 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Post-Intervention Survey
Description: The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
Study NCT03002324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post-Intervention Survey
Description: The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
Study NCT03493061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
Study NCT03493061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
Study NCT03493061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
Study NCT01719458 — intervention group
Intervention type: DRUG
Intervention: (S,S)-[11C]MRB
Description: PET radioligand
Study NCT02088879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chest compression with kneeling position
Study NCT02088879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chest compression with standing position
Study NCT01312805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA Asthma Module
Description: This module was added to CHICA to help diagnose and manage asthma
Study NCT01312805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHICA Control
Description: This is CHICA without the asthma module, and was used as a control
Study NCT03470740 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: rheumatoid arthritis self-management program
Description: The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
Study NCT02793973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shoe lifts
Study NCT02793973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shoe lifts
Study NCT01166893 — intervention group
Intervention type: DEVICE
Intervention: Modulated Imaging and Laser Speckle Imaging
Description: wound healing
Study NCT02402504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non pulse extruded snack
Study NCT02402504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small particle size pea flour
Description: Pulse extruded snack
Study NCT02402504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large particle size pea flour
Description: Pulse extruded snack
Study NCT02402504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lentil flour
Description: Pulse extruded snack
Study NCT02402504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navy bean flour
Description: Pulse extruded snack
Study NCT02402504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinto bean flour
Description: Pulse extruded snack
Study NCT04075747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Up to 2 induction and 2 consolidation courses will be offered
Study NCT04075747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Will be administered over specified duration during induction and consolidation courses
Study NCT04075747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Will be administered over specified duration during induction and consolidation courses
Study NCT04075747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Will be administered over specified duration during induction and consolidation courses
Study NCT04075006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
Study NCT05245110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-exercise training
Description: a 12-week tele-exercise training program
Study NCT03758131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-enhanced Motivational Interviewing
Description: In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use.
Study NCT03758131 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer-enhanced Motivational Interviewing
Description: In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use.
Study NCT03758131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
Study NCT03758131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Control
Description: Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
Study NCT01553682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Horizons+General Health Promotion (GHP)
Description: Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
Study NCT01553682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horizons+Motivational Enhancement Therapy (GMET)
Description: Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
Study NCT02924441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Applied to breast skin
Study NCT01485744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
Description: LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
Study NCT02135835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenfu Zhusheye
Study NCT02135835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose injection
Study NCT02135835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% glucose injection
Study NCT04243083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablet, placebo
Description: Oral QD
Study NCT03993782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A19010-R
Description: A snus product
Study NCT03993782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B19010-O
Description: A snus product
Study NCT03839030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBHP-Educa
Description: This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
Study NCT01119183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACOG education pamphlet on preeclampsia
Description: The ACOG pamphlet on preeclampsia will be offered to this group
Study NCT01119183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preeclampsia education tool
Description: The newly created preeclampsia educational tool will be offered to this group
Study NCT03885752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chewed mint gum
Description: In the preoperative waiting area before transferring to the operating room, patients in group G chewed mint gum for 2 minutes and then spit it out.
Study NCT03885752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: swallow twice
Description: asked to swallow twice without any additional treatment.
Study NCT03101644 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Darunavir
Description: The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
Study NCT01356264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multimodal prehabilitation
Description: multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
Study NCT00496054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Pentavalent vaccine 9G1, G2, G3, G4 \& P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
Study NCT02871700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation therapy
Description: The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
Study NCT02871700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
Study NCT02871700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Customary bilateral UE training
Description: The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
Study NCT02521870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101(1)
Description: SD-101 administered intratumorally at escalating doses (up to 11 doses).
Study NCT02924441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calming Music
Description: Played during mammography
Study NCT02924441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Music
Description: No music played during mammography
Study NCT02579148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUCMSC injection
Description: The subjects will receive intracavernous injection of HUCMSC.'
Study NCT02579148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagen scaffolds/HUCMSC injection
Description: The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
Study NCT01147250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
Study NCT01147250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
Study NCT00752934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral baclofen + placebo
Description: Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur.
Study NCT00752934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo + oral baclofen
Description: Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
Study NCT02521870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
Study NCT02521870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101(2)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
Study NCT00851292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS probe
Description: end-firing and side-firing vary in the angle in which they sample the prostate